Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention of Epilepsy in Stroke Patients at High Risk of Developing Unprovoked Seizures: Anti-epileptogenic Effects of Eslicarbazepine Acetate

NCT06597084 is registered in ClinicalTrials.gov with Bial - Portela C S.A. as lead sponsor.

NCT NCT06597084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06597084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention of Epilepsy in Stroke Patients at High Risk of Developing Unprovoked Seizures: Anti-epileptogenic Effects of Eslicarbazepine Acetate
Lead sponsor
Bial - Portela C S.A.
Phase
Phase 2
Overall status
Completed
Start date
May 29, 2019
Completion date
September 11, 2023
Enrollment
129 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

post stroke epilepsy